Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The safety and efficacy of etavopivat in SCD

Santosh Saraf • 21 Jun 2022
EHA 2022
Non-Malignant Sickle Cell Disease Etavopivat

Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, briefly discusses the safety and efficacy of etavopivat in sickle cell disease (SCD), highlighting the mechanism of action of this agent and promising activity observed in various studies. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding support from FORMA, Global Blood Therapeutics, Novartis, and Pfizer
Serves as a consultant or on an advisory board for Agios, FORMA, Global Blood Therapeutics, Novartis, and ORIC

More from Santosh Saraf

0:53
Improving quality of life outcomes for patients with SCD
Santosh Saraf • 8 Dec 2023
0:45
Current landscape of treatment for SCD: an update from ASH 2023
Santosh Saraf • 8 Dec 2023
0:47
The role of antiphospholipid antibodies in SCD
Santosh Saraf • 8 Dec 2023
0:42
The role of von Willebrand factor in SCD: predicting complications
Santosh Saraf • 8 Dec 2023

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals